Annals of Oncology 12:909-918, 2001
© 2001 European Society for Medical Oncology
research-article |
Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer
1Centre R Gauducheau Nantes
2Aventis Pharma Antonv, France
P Fumoleau, MD Centre Regional de Lutte Contre le Cancer Nantes Atlantique— Site Hospitalier Nord Boulevard Jacques Monod 44805 Nantes — St Herblain France E-mail fumoleau{at}nantes.fnclcc.fr
Background and purpose: Anthracycline-containing regimens are widely used in advanced breast cancer. However, there is a need for new, non-anthracycline regimens that are active in patients for whom anthracyclines are contraindicated. The aim of this study was to determine the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs) and recommended doses of docetaxel and vinorelbine as first-line chemotherapy in patients with metastatic breast cancer. The pharmacokinetics of both drugs was also evaluated.
Patients and methods: Thirty-four women with first-line metastatic breast cancer were treated with docetaxel, 60–100 mg/m2 (day 1), and vinorelbine, 20–22.5 mg/m2 (days 1 and 5), repeated every three weeks and administered on an outpatient basis.
Results: Two MTDs were determined: MTD1 was defined at the dose level using docetaxel 75 mg/m2 and vinorelbine 22.5 mg/m2 DLI being a grade 3 stomatitis that was more related to the dose of vinorelbine than that of docetaxel. There fore, the study continued with a fixed dose of vinorelbine, 20 mg/m2 and docetaxel 85–100 mg/m2 MTD2 was defined at the dose level combining docetaxel. 100 mg/m2 and vinorelbine, 20 mg/m2 DLTs were grade 3 stomatitis and severe asthenia. Fluid retention was observed in 41% of patients but was never severe or a reason for patient discon tinuation. In comparison with historical experience. Daflon 500® did not seem to increase the efficacy of the three-day corticosteroid preniedication by further reducing the incidence or severity of fluid retention. No significant neurotoxicity was observed and no patient discontinued the study due to this site effect. Activity was observed at all dose levels and at all metastatic sites, with an overall response rate of 71% (95% Cl:52.0%–85.8%). The median time to progression was 31.4 weeks (95% CI: 12–48 weeks) and median survival was 15.6 months (95% CI: 2.6–26.6 months). The pharrnacokinetics of docetaxel and vinorelbine were not modified between day I and day 3 when the two drugs were combined with the day I administration schedule used in this study.
Conclusion. The reconiniended doses for phase II studies are docetaxel, 75 mg/m2 (day I), plus vinorelbine, 20 mg/m2 (days 1 and 5), repeated every three weeks. At these doses, the combination was found to be active and well tolerated.
breast cancer, docetaxel, phase I, vinorelbine